Evvy Raises $40M to Bring Vaginal Microbiome Testing Into Fertility Care
Evvy has raised a $40 million Series B led by Catalio Capital Management. The company announced the round on Tuesday, September 15, 2026. TechCrunch
Evvy was launched in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro. Jain serves as chief executive. The company says it now serves more than 100,000 patients across the United States and works with 3,000 practitioners.
Its core product is an at-home test that uses metagenomic next-generation sequencing, or mNGS, to identify vaginal microbes from a single swab. The method reads all microbial DNA in the sample at once, like taking a census rather than searching for one organism at a time. Evvy says the assay is CLIA-certified and CLEP-certified, two laboratory quality certifications, and detects more than 700 bacteria and fungi. Every result is reviewed by a licensed clinician and paired with a customized plan that can include targeted prescriptions where eligible. The company also offers a membership to track how treatments and behaviors affect the vaginal microbiome over time. Evvy
Catalio Capital Management, a New York-based investment firm focused on healthcare investing across private, public and credit markets, led the financing. The Series B added new investors including the U.S. Fertility Innovation Fund, Rethink Impact and Muse Capital. SiliconANGLE
Evvy plans to expand its vaginal microbiome platform into reproductive healthcare, starting with fertility and IVF. The company aims to make vaginal microbiome testing routine. Beauty Independent
That clinical expansion is paired with a research program built on the same sequencing infrastructure. Evvy says it has generated 15 peer-reviewed publications and abstracts. It says it has identified novel bacterial vaginosis subtypes and discovered hundreds of previously uncatalogued vaginal microbiome genomes.
On the product side, Evvy in May started offering an AI assistant called EvvyAI, billed as an advisor for vaginal health. It has also launched a prospective study leveraging its vaginal microbiome tests in IVF clinics.
The broader context here will be familiar to anyone who has followed diagnostics. A single at-home swab can start a patient relationship. Follow-up sampling, clinician review and prescription pathways sustain it. Research output then increases the value of each new sample.
Looking at what this means for fertility workflows, the IVF focus is practical. Clinics already follow structured protocols with clear endpoints. Adding microbiome sequencing to that process creates detailed data tied to specific time points. It also places Evvy in a referral channel with motivated patients and specialist oversight, rather than relying only on direct-to-consumer sales.
In my view, the interesting technical bet combines sequencing depth with an AI interface and human clinical review, more than mNGS sensitivity alone. Automated guidance lowers friction for patients dealing with recurrent symptoms. Clinician oversight provides limits. Whether that balance scales across thousands of practitioners will depend on integration work that rarely makes funding announcements, including EHR fit, clear results and defined escalation paths. If Evvy gets that right, microbiome testing could become standard input for care, giving clinicians more detailed data for conditions long treated with broad tools.
